• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Embla Medical hf (CPSE:EMBLA), What Is Driving The Latest Attention?

    Simply Wall St·10/25/2026 08:29:25
    Listen to the news

    Why Embla Medical hf Stock Just Moved

    Embla Medical hf (CPSE:EMBLA) just released third quarter and nine month earnings, reporting sales of US$249.58 million and net income of US$26.13 million for the quarter compared with the prior year period.

    Today’s earnings helped Embla Medical hf break a short streak of weaker trading, with a 1-day share price return of 1.34%. However, the 90-day share price return is still down 5.85% and the 1-year total shareholder return has declined 21.45%, suggesting sentiment is only starting to repair after a tougher year.

    Scan how Embla Medical hf compares with other healthcare specialists that have been hand-picked for resilient fundamentals and cleaner balance sheets through our list of solid balance sheet and fundamentals (205 results).

    Embla Medical hf just posted steadier sales and earnings while the share price is still down over 1 year. Is this latest uptick pricing in better fundamentals, or just a short burst of optimism before valuations are tested next?

    Most Popular Narrative: 21% Undervalued

    Embla Medical hf closed at DKK26.55, while the most followed narrative assigns a fair value of DKK33.60 based on a 7.16% discount rate. That gap puts the focus firmly on whether the current execution in core prosthetics and clinics can support the cash flow profile implied in that estimate.

    The main factor that has to go right is that Embla Medical executes on its Patient Care transformation and manufacturing consolidation so that clinic growth and cost savings materialise without eroding its 21% EBITDA margin profile.

    The numbers imply that Embla Medical’s current share price does not fully reflect the cash flow potential suggested by its 5% organic sales growth, roughly 21% EBITDA margin and the external DCF analysis indicating the stock may be significantly undervalued.

    See why 4 investors see Embla Medical hf as 21% undervalued.

    Result: Fair Value of DKK33.60 (UNDERVALUED)

    Still, flat Patient Care clinic sales and pressure from lower growth in Bracing and Supports could quickly weaken the Embla Medical hf undervaluation story.

    Find out about the key risks to this Embla Medical hf narrative.

    Next Steps

    Sentiment around Embla Medical hf is split, and that is exactly when it pays to move quickly and inspect the underlying numbers yourself. To see why some investors still highlight potential upsides in the story, review the 5 key rewards.

    Looking for more investment ideas beyond Embla Medical hf?

    If Embla Medical hf has sharpened your focus on quality and valuation, do not stop here. Use the screener tools to pressure test fresh ideas before the crowd notices.